Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

HALOA: Cardiac Coherence With CPAP for Obstructive Sleep Apnea (HALOA)

5. listopadu 2026 aktualizováno: Bughin Francois, Clinique du Millenaire

Effect of Adding Cardiac Coherence to Continuous Positive Airway Pressure in Patients With Obstructive Sleep Apnea: A Multicenter Randomized Delayed-Start Controlled Study

This multicenter study will evaluate whether adding cardiac coherence breathing sessions to continuous positive airway pressure (CPAP) improves sleep quality in adults with newly diagnosed obstructive sleep apnea who are starting CPAP. Approximately 180 participants will be randomly assigned to one of two groups. Both groups will start treatment with the HALOA CPAP system. In one group, the cardiac coherence module will be activated at the start of treatment. In the other group, participants will use CPAP alone for 8 weeks before the module is activated.

Sleep quality will be assessed at study entry, at 8 weeks, and at 16 weeks using the Pittsburgh Sleep Quality Index. The primary comparison will assess the change in sleep quality from study entry to week 8 between the two groups. Secondary assessments will include daytime sleepiness, insomnia symptoms, anxiety and depression symptoms, treatment satisfaction, usability of the cardiac coherence module, CPAP use, and heart-rate variability when polysomnography recordings are available.

Přehled studie

Detailní popis

Obstructive sleep apnea is commonly treated with continuous positive airway pressure (CPAP). However, some patients have difficulty adhering to CPAP or experience persistent sleep-related symptoms. Cardiac coherence is a guided breathing practice intended to support relaxation and emotional regulation. The HALOA system combines CPAP treatment with a cardiac coherence module. This study will assess whether access to this module from the start of CPAP treatment improves subjective sleep quality compared with starting the module after an initial period of CPAP alone.

This is a prospective, multicenter, randomized, open-label, delayed-start controlled study. Approximately 180 adults with newly diagnosed obstructive sleep apnea and an indication for CPAP will be enrolled at 11 planned centers. Participants will be randomly assigned in equal numbers to one of two groups.

All participants will begin CPAP treatment using the HALOA system and will receive usual CPAP care. Participants in the immediate-intervention group will have the cardiac coherence module activated at study entry and will receive guidance on its use. Participants in the delayed-intervention group will use CPAP without cardiac coherence for the first 8 weeks. After the week 8 assessment, the module will be activated and participants will receive guidance on its use.

Study assessments will take place at baseline, week 8, and week 16. The primary outcome is the change in the global Pittsburgh Sleep Quality Index (PSQI) score from baseline to week 8, comparing the two randomized groups. The week 8 assessment provides the controlled comparison before participants in the delayed-intervention group begin cardiac coherence. Changes in PSQI from week 8 to week 16 in the delayed-intervention group will also be assessed to explore the effect after the module is introduced.

Secondary assessments will include daytime sleepiness using the Epworth Sleepiness Scale, insomnia symptoms using the Insomnia Severity Index, and anxiety and depression symptoms using the Hospital Anxiety and Depression Scale. Patient satisfaction will be assessed using the CSQ-8 and a study-specific questionnaire. Usability of the cardiac coherence module will be assessed using the System Usability Scale. CPAP adherence will be evaluated using device data, including hours of use and the proportion of participants meeting the protocol-defined adherence threshold. Heart-rate variability indices will be evaluated from polysomnography recordings when available.

Participants will be adults with obstructive sleep apnea diagnosed by polysomnography within the 3 months before inclusion and for whom CPAP treatment is indicated. The protocol lists recent CPAP or mandibular advancement device treatment, refusal of or contraindication to CPAP, inability to use the cardiac coherence device, and specified medical, psychiatric, or other circumstances among the non-inclusion criteria.

Typ studie

Intervenční

Zápis (Odhadovaný)

180

Fáze

  • Nelze použít

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

  • Jméno: François FB Bughin, Md, PhD
  • Telefonní číslo: 0033761783081
  • E-mail: fbughin@hotmail.com

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let až 80 let (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • Age 18 years or older.
  • Obstructive sleep apnea diagnosed according to ICSD-3 criteria by polysomnography performed within 3 months before study inclusion.
  • Indication for CPAP treatment according to current recommendations: apnea-hypopnea index (AHI) ≥30 events/hour, or AHI ≥15 events/hour with severe cardiovascular or respiratory comorbidity.
  • Written informed consent.

Exclusion Criteria:

  • CPAP or mandibular advancement device treatment within the 3 months before inclusion.
  • Refusal of CPAP treatment.
  • Contraindication to CPAP treatment.
  • Unstable psychiatric disorder or substance-use disorder.
  • Technical inability to use the cardiac coherence device.
  • Not affiliated with, or not a beneficiary of, a social security system.
  • Deprivation of liberty by judicial or administrative decision.
  • Legal protective measure, including guardianship or curatorship.
  • Pregnancy, childbirth, or breastfeeding.
  • Language barrier preventing participation.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Singl

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Immediate cardiac coherence with CPAP

Participants will start HALOA CPAP at study inclusion. The cardiac coherence breathing module will be activated from the start of treatment, with guidance on its use. Participants will be assessed at baseline, week 8, and week 16.

CPAP treatment using the HALOA system, initiated at study inclusion in both groups and provided as part of usual care.

Guided cardiac coherence breathing sessions using the module integrated with the HALOA system. The module is activated at study inclusion in the experimental group and after the week 8 assessment in the active comparator group.

Aktivní komparátor: Delayed cardiac coherence with CPAP

Participants will start HALOA CPAP at study inclusion and use it without the cardiac coherence module for 8 weeks. After the week 8 assessment, the module will be activated and guidance on its use provided. Participants will be assessed at baseline, week 8, and week 16.

CPAP treatment using the HALOA system, initiated at study inclusion in both groups and provided as part of usual care.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Change in Global Pittsburgh Sleep Quality Index (PSQI) Score
Časové okno: Baseline to week 8

Absolute change in the global PSQI score from baseline (V1) to week 8 (V2), comparing the randomized groups. PSQI scores range from 0 to 21; higher scores indicate poorer sleep quality.

Baseline to week 8

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Change in PSQI Score After Delayed Initiation of Cardiac Coherence
Časové okno: Week 8 to week 16

Absolute change in global PSQI score from week 8 (V2) to week 16 (V3) in the delayed-intervention group, after the cardiac coherence module is activated.

Week 8 to week 16
Change in Daytime Sleepiness
Časové okno: Baseline, week 8, and week 16

Changes in Epworth Sleepiness Scale (ESS)

Baseline, week 8, and week 16
Change in insomnia symptoms
Časové okno: Baseline, week 8, and week 16

Changes in Insomnia Severity Index (ISI)

Baseline, week 8, and week 16
Change in depression symptoms
Časové okno: Baseline, week 8, and week 16

Changes in Hospital Anxiety and Depression Scale anxiety and depression subscale scores (HADS-A and HADS-D).

Baseline, week 8, and week 16
Patient Satisfaction
Časové okno: Baseline, week 8, and week 16, as applicable

Patient satisfaction measured using the Client Satisfaction Questionnaire (CSQ-8) and the study-specific S-HALOA-CC questionnaire. S-HALOA-CC results will be considered exploratory.

Baseline, week 8, and week 16, as applicable
Usability of the Cardiac Coherence Module
Časové okno: Week 8 for the immediate-intervention group and week 16 for the delayed-intervention group

Usability measured using the System Usability Scale (SUS) after exposure to the cardiac coherence module.

Week 8 for the immediate-intervention group and week 16 for the delayed-intervention group
CPAP Adherence
Časové okno: At weeks 8 and 16; device use assessed over the 7-day and 30-day periods before each visit

Mean nightly CPAP use and the proportion of participants meeting the protocol-defined adherence threshold of at least 4 hours per night on at least 70% of nights.

At weeks 8 and 16; device use assessed over the 7-day and 30-day periods before each visit
Heart-Rate Variability
Časové okno: Baseline and week 16, when recordings are available

Changes in time-domain and frequency-domain heart-rate variability indices derived from polysomnography recordings, when follow-up recordings are available.

Baseline and week 16, when recordings are available
Clinically Meaningful Improvement in Sleep Quality
Časové okno: Baseline to week 8, week 8 to week 16, and baseline to week 16

Proportion of participants with a decrease of at least 3 points in global PSQI score over the specified assessment interval.

Baseline to week 8, week 8 to week 16, and baseline to week 16

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

1. listopadu 2026

Primární dokončení (Odhadovaný)

1. června 2028

Dokončení studie (Odhadovaný)

1. prosince 2028

Termíny zápisu do studia

První předloženo

5. listopadu 2026

První předloženo, které splnilo kritéria kontroly kvality

5. listopadu 2026

První zveřejněno (Aktuální)

10. listopadu 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

10. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

5. listopadu 2026

Naposledy ověřeno

1. listopadu 2026

Více informací

Termíny související s touto studií

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NEROZHODNÝ

Popis plánu IPD

The sponsor has not yet determined whether individual participant data and the corresponding data dictionary will be made available to other researchers. The plan will be updated once a decision has been made.

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit